Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| microglial cell | 11 studies | 56% ± 16% | |
| endothelial cell | 10 studies | 25% ± 7% | |
| macrophage | 8 studies | 31% ± 14% | |
| GABAergic neuron | 6 studies | 36% ± 18% | |
| myeloid cell | 6 studies | 21% ± 6% | |
| glutamatergic neuron | 5 studies | 35% ± 20% | |
| podocyte | 5 studies | 53% ± 22% | |
| interneuron | 5 studies | 37% ± 23% | |
| dendritic cell | 4 studies | 26% ± 7% | |
| oligodendrocyte precursor cell | 4 studies | 24% ± 6% | |
| endothelial cell of lymphatic vessel | 4 studies | 22% ± 5% | |
| capillary endothelial cell | 3 studies | 18% ± 3% | |
| monocyte | 3 studies | 23% ± 6% | |
| type I pneumocyte | 3 studies | 18% ± 3% | |
| granule cell | 3 studies | 28% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 6 studies | 39% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 1461.83 | 2639 / 2642 | 100% | 8.65 | 704 / 705 |
| ovary | 100% | 816.15 | 180 / 180 | 99% | 4.44 | 424 / 430 |
| breast | 100% | 747.06 | 459 / 459 | 97% | 3.31 | 1080 / 1118 |
| esophagus | 100% | 658.58 | 1439 / 1445 | 97% | 3.83 | 177 / 183 |
| skin | 100% | 1294.23 | 1808 / 1809 | 96% | 6.89 | 451 / 472 |
| lung | 100% | 978.32 | 577 / 578 | 95% | 2.57 | 1099 / 1155 |
| uterus | 100% | 737.95 | 170 / 170 | 93% | 3.32 | 429 / 459 |
| adrenal gland | 100% | 703.93 | 258 / 258 | 93% | 2.59 | 214 / 230 |
| thymus | 99% | 556.82 | 649 / 653 | 93% | 2.47 | 562 / 605 |
| prostate | 100% | 535.78 | 244 / 245 | 90% | 2.19 | 452 / 502 |
| kidney | 100% | 872.08 | 89 / 89 | 82% | 2.48 | 735 / 901 |
| bladder | 100% | 604.24 | 21 / 21 | 79% | 2.34 | 396 / 504 |
| stomach | 82% | 340.24 | 293 / 359 | 67% | 2.03 | 191 / 286 |
| intestine | 95% | 675.09 | 919 / 966 | 46% | 1.18 | 245 / 527 |
| liver | 73% | 204.35 | 164 / 226 | 65% | 1.52 | 265 / 406 |
| pancreas | 39% | 104.96 | 127 / 328 | 95% | 3.11 | 169 / 178 |
| spleen | 100% | 851.44 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.94 | 1 / 1 |
| blood vessel | 100% | 947.72 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 985.82 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 2.48 | 41 / 45 |
| heart | 85% | 377.27 | 733 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 69% | 1.40 | 20 / 29 |
| peripheral blood | 63% | 196.08 | 588 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 39% | 0.91 | 31 / 80 |
| muscle | 21% | 53.61 | 170 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0021816 | Biological process | extension of a leading process involved in cell motility in cerebral cortex radial glia guided migration |
| GO_1904862 | Biological process | inhibitory synapse assembly |
| GO_0021987 | Biological process | cerebral cortex development |
| GO_1904861 | Biological process | excitatory synapse assembly |
| GO_0051490 | Biological process | negative regulation of filopodium assembly |
| GO_0051963 | Biological process | regulation of synapse assembly |
| GO_0061000 | Biological process | negative regulation of dendritic spine development |
| GO_2001224 | Biological process | positive regulation of neuron migration |
| GO_0098978 | Cellular component | glutamatergic synapse |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0042803 | Molecular function | protein homodimerization activity |
| Gene name | SRGAP2C |
| Protein name | SLIT-ROBO Rho GTPase-activating protein 2C (SLIT-ROBO Rho GTPase activating protein 2 pseudogene 1) SLIT-ROBO Rho GTPase activating protein 2C |
| Synonyms | SRGAP2P1 |
| Description | FUNCTION: Human-specific protein that acts as a key modifier of cortical connectivity in the human brain . Acts by inhibiting the functions of ancestral paralog SRGAP2/SRGAP2A, a postsynaptic protein that regulates excitatory and inhibitory synapse maturation and density in cortical pyramidal neurons . SRGAP2C is unstable but is able to heterodimerize with SRGAP2/SRGAP2A, thereby reducing SRGAP2/SRGAP2A levels through proteasome-dependent degradation . Inhibition of SRGAP2/SRGAP2A by SRGAP2C leads to an increase in synaptic density and protracted synaptic maturation of both excitatory and inhibitory synapses . Modifies cortical circuit connectivity by increasing the number of local and long-range cortical inputs received by layer 2/3 pyramidal neurons . Also able to increase the probability of sensory-evoked responses by layer 2/3 pyramidal neurons . . |
| Accessions | ENST00000367123.8 ENST00000304465.7 A0A087X0L1 P0DJJ0 |